← All trials

NCT07184944

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jan 29, 2026
Primary completion
Aug 13, 2029
Completion date
Mar 20, 2034
First posted
Sep 22, 2025
Last posted
Oct 2, 2025
Enrollment
671
Arms / groups
4 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.